Federated Hermes Inc. Lowers Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Federated Hermes Inc. lowered its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 46.4% during the 4th quarter, HoldingsChannel reports. The fund owned 22,640 shares of the company’s stock after selling 19,564 shares during the period. Federated Hermes Inc.’s holdings in Nurix Therapeutics were worth $427,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Barclays PLC raised its position in shares of Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Nurix Therapeutics by 9.6% during the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company’s stock valued at $32,544,000 after acquiring an additional 126,306 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in Nurix Therapeutics by 8.4% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock worth $675,000 after acquiring an additional 2,329 shares during the last quarter. Franklin Resources Inc. boosted its stake in Nurix Therapeutics by 52.4% during the 3rd quarter. Franklin Resources Inc. now owns 123,101 shares of the company’s stock valued at $2,766,000 after purchasing an additional 42,315 shares during the last quarter. Finally, Lord Abbett & CO. LLC bought a new stake in shares of Nurix Therapeutics in the 3rd quarter worth $7,879,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on NRIX shares. Morgan Stanley lifted their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, February 3rd. Stephens restated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, January 21st. Leerink Partners assumed coverage on shares of Nurix Therapeutics in a research note on Monday, March 17th. They set a “market perform” rating and a $16.00 target price for the company. Needham & Company LLC dropped their price target on Nurix Therapeutics from $28.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. Finally, Leerink Partnrs raised Nurix Therapeutics to a “hold” rating in a research report on Monday, March 17th. Three equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.44.

Insider Buying and Selling

In other news, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Houte Hans Van sold 5,825 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the sale, the chief financial officer now directly owns 33,724 shares in the company, valued at $488,660.76. This trade represents a 14.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock worth $213,449 over the last three months. 7.20% of the stock is owned by insiders.

Nurix Therapeutics Stock Up 4.5 %

Nurix Therapeutics stock opened at $10.24 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $29.56. The company has a market cap of $780.66 million, a price-to-earnings ratio of -3.54 and a beta of 2.23. The firm’s fifty day moving average is $13.32 and its 200 day moving average is $18.85.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. The company had revenue of $18.45 million during the quarter, compared to analyst estimates of $12.78 million. During the same quarter last year, the business posted ($0.76) earnings per share. On average, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.